trial · primary record
Telisotuzumab Vedotin
Non Small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 768 |
| Primary completion | 2029-02 |
| Primary endpoint | Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) |
| Registry ID | NCT04928846 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:27.088Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04928846
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.